Survodutide

Used for

• Weight loss
• MASH (fatty liver with inflammation and scarring)
• Type 2 diabetes with obesity

How it works

GLP-1 action cuts appetite; glucagon action adds energy burn and lowers liver fat.

What the research shows

• Phase 2 (46 weeks, 387 adults without diabetes): 0.6, 2.4, 3.6 and 4.8 mg a week lost 6.2%, 12.5%, 13.2% and 14.9% vs 2.8% on placebo. Stomach side effects hit 75% vs 42%; about 60% finished the 46 weeks in both groups.
• SYNCHRONIZE-1 (phase 3, 76 weeks, no diabetes): 3.6 and 6.0 mg lost 12.2% and 13.0% vs 5.4% on placebo; stomach side effects in 81% and 90% vs 48%.
• SYNCHRONIZE-2 (phase 3, obesity with type 2 diabetes): 8.2% on 3.6 mg and 9.8% on 6.0 mg vs 3.9%.
• MASH phase 2 (48 weeks, 293 people): MASH improved without worse scarring in 47%, 62% and 43% on 2.4, 4.8 and 6.0 mg vs 14% on placebo. Nausea 66% vs 23%, vomiting 41% vs 4%, diarrhea 49% vs 23%.

Dosing

Dosing isn’t listed on the public site. In the app, each published option is shown with its source (a drug label, a clinical guideline, a trial or community reports) and can be turned into a protocol you review.

Side effects

• Nausea, especially after a dose step
• Constipation or diarrhea
• Reflux, burping
• Lower appetite and thirst: dehydration risk
• Vomiting and diarrhea were common in the MASH trial (41% and 49%)

Cautions

• Not for anyone with a personal or family history of medullary thyroid cancer or MEN2.
• Pancreatitis and gallbladder problems are uncommon but reported; severe belly pain needs urgent care.
• Rapid weight loss costs muscle too: keep protein high and keep lifting.
• Stop before planned surgery or sedation per your doctor (slower stomach emptying).
• Not approved: long-term safety is still being studied.
• Research-chemical vials have no quality control: purity, dose and sterility vary. Third-party testing helps but is no guarantee.

Storage

More in Weight & metabolic